Evidence map›Paper›PMID 38867583›Full record

ArticleHaematologica2024

An investigation of germline variants of

Jinjun Cheng, Liqiang Xi, Yoon Jang, Jung Kim, Hao-Wei Wang, Stefania Pittaluga, Elaine S Jaffe, Mark Raffeld

Abstract readLetter
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinjun ChengCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Division of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC; Departments of Pathology and Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
Liqiang XiCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Yoon JangCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Jung KimCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Hao-Wei WangCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Stefania PittalugaCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Elaine S JaffeCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mark RaffeldCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. mraff@mail.nih.gov.

Funding

Molecular Diagnostics Core LaboratoryZICBC011079 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI XI, LIQIANG · 2009 to 2025
$33.8M
Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Hematopathology DiagnosisZIABC011070 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$14.5M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Germ-Line MutationHepatitis A Virus Cellular Receptor 2Lymphoma, T-CellPanniculitisFemaleGenetic Predisposition to DiseaseHumansMaleNorth AmericaHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2

Identifiers

PMID38867583
PMCPMC11443401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.